Epilepsy Devices Market Size

Epilepsy Devices Market Overview

The Epilepsy devices market Size was valued at USD 1.3 billion in 2021 and is projected to grow from USD 1.4 Billion in 2022 to USD 2.6 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.20% during the forecast period (2022 - 2030). Rising frequency of cervical spondylosis among corporate workers and the increasing occurrences of cervical injuries in vehicle accidents are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Epilepsy Devices Market Trends

• The considerable potential in undeveloped, emerging markets is projected to drive epilepsy device market growth

The Epilepsy Devices Industry The availability of enhanced healthcare infrastructure, an increase in unmet healthcare requirements, an increase in the prevalence of epilepsy, and a surge in demand for conventional and wearable epilepsy devices are likely to fuel growth in unexplored, emerging countries. Furthermore, the healthcare industry in emerging nations is expanding rapidly, owing to increased demand for improved healthcare services and large government investments in healthcare infrastructure. The need for epilepsy gadgets is not confined to developed countries; it is also seen in developing countries such as China, Japan, and India, which fuels the market's growth. The key Epilepsy Devices Market Opportunity in the coming years will be driven by factors such as an increase in the incidence of ischemic stroke, an increased focus on developing cost-effective epilepsy devices, an increase in R&D investments in the discovery and development of advanced epilepsy devices, and an increase in awareness about the use of epilepsy devices for epilepsy diagnosis and monitoring.

Moreover, Growth and innovation in the medical device industry for the manufacturing of epileptic devices, owing to a large pool of health-conscious customers, presents an opportunity for the epilepsy devices market. The rise in the proportion of elderly people who are more sensitive to epilepsy is the primary factor driving market expansion. Growth and innovation in the medical device industry for the manufacturing of epileptic devices, owing to a large pool of health-conscious customers, presents an opportunity for the epilepsy devices market. The rise in the proportion of elderly people who are more sensitive to epilepsy is the primary factor driving market expansion.

For instance, the National Center for Health Statistics reports that over 795,000 people in the United States have a stroke each year. Furthermore, the Centers for Disease Control and Prevention (CDC) reports that ischemic strokes account for approximately 87% of all documented strokes.

However, severe government regulations are the main impediments to the manufacture and approval of epilepsy gadget solutions. Many governments have distinct regulations in place to oversee the entry of new devices and technologies. Different regulatory authorities provide different guidelines, and the introduction of new things must strictly follow them. The introduction of new products may be delayed due to the complex and time-consuming clearance procedures. Furthermore, the high cost of EEG and electrocardiography (ECG) devices is expected to limit the Epilepsy Devices Market Size in the approaching years.

Epilepsy Devices Market Segment Insights

Epilepsy Devices Product Type Insights

The epilepsy devices market segmentation, based on product type, includes Conventional Devices, Wearable Devices, Implantable Devices, Diet and others. The conventional and wearable devices segment dominated the global market in 2021 and is anticipated to maintain its dominance throughout the forecast period. This is because of its benefits, including ease of portability, exceptional wireless readability, higher sensitivity rates in detecting seizures, increased mobility and quality of life for epilepsy patients, and the ability to track the remote location of the epileptic patients, which is helpful in cases of a seizure attack.

Epilepsy Devices Technology Insights

The epilepsy devices market segmentation, based on technology, includes Vagus Nerve Stimulation, Deep Brain Stimulation, Accelerometery, Responsive Neurostimulation and others. During the projected period, it is expected that the deep brain stimulation segment will continue to dominate the global market, as it did in 2021. Deep brain stimulators are becoming more and more popular, which is responsible for this. Deep brain stimulators are increasingly being used to treat a variety of neuromuscular conditions, including Parkinson's disease, epilepsy, and dystonia, which contributes to the expansion of the segmental market.

Epilepsy Devices End User Insights

Based on End Users, the global epilepsy devices industry has been segmented into Hospitals and Clinics, Neurology Centers, Home Care Settings and Others. The hospital sector accounted for the largest market share for epilepsy devices in 2021, and it is anticipated to maintain its dominance throughout the forecast period. This is because hospitals have access to trained medical staff, which enables them to offer patients better services and offers additional advantages for the diagnosis and treatment of neuromuscular disorders, including epilepsy.

Figure 2: Epilepsy devices market, by End User, 2021& 2030(USD Million)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Epilepsy Devices Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. In 2021, North America accounted for a significant share of the epilepsy devices market and is expected to maintain its dominance during the fast period. Furthermore, the increase in the number of patients undergoing neurosurgical procedures in this region contributes to the growth of the market. Furthermore, high purchasing power and an increase in epilepsy device adoption are expected to drive market growth.

Further, the major countries studiedin the market reportare: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: Epilepsy devices market SHARE BY REGION 2021 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe epilepsy devices market accounts for the second-largest market share due to an increase in healthcare spending and the presence of a large geriatric population. Further, the Germany epilepsy devices market held the largest market share, and the UK epilepsy devices market was the fastest growing market in the European region.

The Asia-Pacific Epilepsy Devices Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due to the presence of medical device companies in the region, as well as the rising purchasing power of populated countries like China and India. Furthermore, the rising cost of healthcare and the increasing use of epilepsy devices such as surface electromyography, EEG systems, and accelerometers drive market expansion.  Moreover, China epilepsy devices market held the largest market share, and the India epilepsy devices market was the fastest growing market in the Asia-Pacific region.

Epilepsy Devices Key Market Players & Competitive Insights

Major industry players are investing a lot of money in R&D to expand their product offerings, which will spur further growth in the epilepsy devices market. With significant market developments like new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market participants are also undertaking a variety of strategic activities to expand their global presence. In order to grow and survive in an environment where competition is fierce and the economy is booming, competitors in the epilepsy device industry must provide affordable products.

Manufacturing locally to cut operational costs is one of the main business methods used by manufacturers in the worldwide epilepsy devices industry to benefit customers and increase the market sector. Some of medicine's most important recent advances have come from the epilepsy gadgets business. Major players in the epilepsy device market include Boston Scientific Corporation, Natus Medical Incorporated, Nihon Kohden Corporation, MC10, Empatica Inc., and NeuroPace, Inc. (US)

Medtronic Inc. (Ireland) is a global healthcare solutions provider dedicated to enhancing people's lives via medical technologies, services, and solutions. With Covidien, the firm has accelerated and enhanced its ability to generate meaningful breakthroughs that enable hospitals, health systems, and healthcare providers to give the best possible care to patients and their families around the world. In June 2021, Vanta is an implantable neurostimulator from Medtronic plc that offers great performance without requiring a recharge.

Neuronetics is a publicly traded company situated in Malvern, Pennsylvania that was founded in Delaware in April 2003[4] to research non-invasive treatments for psychiatric diseases that have shown resistance or lack of response with standard medicine. Neuromodulation technology is used in the therapies. In September 2020, Neuronostics was awarded funding to develop its BioEP platform, an AI-based system for faster, more accurate epilepsy diagnosis and monitoring response to anti-epileptic drug treatment (ADs)

Key Companies in the epilepsy devices market includes

• LivaNova Plc (UK)


• Medtronic Plc (Ireland),


• Medpage Ltd (UK),


• Koninklijke Philips NV (Netherlands)


• Compumedics Limited (Australia)


• Natus Medical Incorporated (US)


• Nihon Kohden Corporation (Japan)


• MC10 (US), Empatica Inc (US)


• NeuroPace Inc (US)


• Boston Scientific Corporation (US)among others

Epilepsy Devices Industry Developments

In February 2019, Philips teamed with researchers from Eindhoven University of Technology, Kempenhaeghe, and Ghent University in Belgium to develop a method to stimulate the brain using electrodes put on the head rather than inside it. Their goal is to tailor treatment for those suffering from severe epilepsy.

In March 2020, the FDA approved the NeuroPace RNS System for MRI labeling, allowing thousands more patients to benefit from personalized, data-driven epilepsy treatment.

In May 2020, Magstirn acquired Philips' subsidiary EGI, expanding its product portfolio with high-density EEG solutions. This acquisition aided the company in closing the loop on the development of a comprehensive non-invasive system.

Epilepsy Devices Market Segmentation

Epilepsy Devices Product Type Outlook

• Conventional Devices


• Wearable Devices


• Implantable Devices


• Diet

Epilepsy Devices Technology Outlook

• Vagus Nerve Stimulation


• Deep Brain Stimulation


• Accelerometery


• Responsive Neurostimulation

Epilepsy Devices End User Outlook

• Hospitals and Clinics


• 
  Neurology Centers


• Home Care Settings

Epilepsy Devices Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report